Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
EU-India Pharmaceutical Trade: Opportunities and Challenges in Biopharmaceutical Innovation
A European Federation of Pharmaceutical Industries and Associations (EFPIA) statement has welcomed the European Union’s progress in concluding negotiations for a Free Trade Agreement with India. EU-India Pharmaceutical Trade relations have gained strategic importance amid geopolitical uncertainty...
Nonclinical Safety Testing with Virtual Control Groups
Virtual Control Groups are set to reduce animal use in medicines development. The European Medicines Agency (EMA) has released a draft Qualification Opinion endorsing the use of Virtual Control Groups to replace or reduce concurrent control groups in non-GLP rat dose-range finding studies.
Advancing Participatory Arts Health in Dutch Care Systems
Participatory arts health is gaining recognition as a valuable complement to traditional medical care, supporting both physical and psychosocial well-being for people living with chronic conditions and those at the end of life. In this article we explore how creative, participatory approaches ...